Effect of candesartan on New York Heart Association functional class. Results of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme.
Effect of candesartan on New York Heart Association functional class. Results of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme.
复制标题
坎地沙坦对纽约心脏协会功能分级的影响。
DOI：
10.1016/j.ehj.2004.07.025
复制
发表时间：
2004
影响因子：
39.3
通讯作者：
K. Swedberg
中科院分区：
文献类型：
--
作者：
E. O’Meara;S. Solomon;J. McMurray;M. Pfeffer;S. Yusuf;E. Michelson;C. Granger;B. Olofsson;James B. Young;K. Swedberg
AimsTo评估血管紧张素受体阻滞剂坎地沙坦对慢性心力衰竭（CHF）患者纽约心脏协会（NYHA）心功能分级的影响。方法和结果CHARM项目中有症状CHF患者随机分为安慰剂组（n=3796）和坎地沙坦组（n=3803），随访中位时间为38个月。在基线时、剂量调整期间每隔两周以及此后每隔4个月评估一次NYHA分级。与基线相比，患者在研究结束时被分类为“更好”、“不变”或“更差”。使用了简单的“末次访视结转”（LVCF）分析和“最差等级结转”（WRCF）分析（其中死亡患者被分配为NYHA V级）。在LVCF分析中，与安慰剂组相比，坎地沙坦组NYHA分级改善的患者更多（35.4% vs 32.5%），恶化的患者更少（9.0% vs 10.3%）（p=0.003）。WRCF分析还显示，坎地沙坦组NYHA分级的总体变化优于安慰剂组。有没有异质性之间的CHARM组件trials.ConclusionsCantesartan的反应改善NYHA功能分级到类似程度的其他证明治疗CHF时，添加到这些其他治疗。
AimsTo evaluate the effect of the angiotensin receptor blocker candesartan on New York Heart Association (NYHA) functional class in a broad spectrum of patients with chronic heart failure (CHF).Methods and resultsPatients in the CHARM Programme with symptomatic CHF were randomized to placebo (n=3796) or candesartan (n=3803) and followed for a median of 38 months. NYHA class was assessed at baseline, at two weekly intervals during dose titration and 4 monthly thereafter. Patients were classified as "better", "unchanged" or "worse" at the end of the study compared to baseline. Both a simple "last visit carried forward" (LVCF) analysis and "worst rank carried forward" (WRCF) analysis (where patients who died were allocated NYHA class V) were used. In the LVCF analysis, compared to placebo, more candesartan patients improved (35.4% versus 32.5%) and fewer worsened (9.0% versus 10.3%) in NYHA class (p=0.003). The WRCF analysis also showed a better overall change in NYHA class with candesartan compared to placebo. There was no heterogeneity in the response to candesartan between the CHARM component trials.ConclusionsCandesartan improves NYHA functional class to a similar extent to other proven treatments for CHF when added to these other treatments.
通过 6 分钟步行测试预测左心室功能障碍患者的死亡率和发病率。
DOI：
--
发表时间：
1993
期刊：
JAMA : the journal of the American Medical Association
影响因子：
--
作者：
Bittner,V;Weiner,DH;Yusuf,S;Rogers,WJ;McIntyre,KM;Bangdiwala,SI;Kronenberg,MW;Kostis,JB;Kohn,RM;Guillotte,M
通讯作者：
Guillotte,M